Defence Therapeutics Inc. is a Canada-based clinical-stage biotechnology company. The Company is engaged in developing and engineering the antibody drug conjugates (ADC) products using its proprietary platform. Its principal business activity is the development of a biological drug enhancer platform that improves the efficacy and safety of a multitude of biological-/biosimilar-based pharmaceuticals used in the treatment of cancer and infectious diseases. The core of its therapeutics platform is the ACCUM technology, which enables precision delivery ADCs in their intact form to target cells. The Company is focused on research, development and advancement of the main products using its Accum technology, which include ADC targeting various cancers, Anti-cancer AccuTOX program, Mesenchymal stromal cell-based vaccine (ARM-X) targeting cancer, mRNA vaccination, Cervical cancer vaccine, and Radio-immunoconjugates (RIC) targeting various cancers.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
02/09/26	CA$0.5200	0.00%	32,595
01/09/26	CA$0.5200	-3.70%	13,443
31/08/26	CA$0.5400	+3.85%	75,296
28/08/26	CA$0.5200	+1.96%	24,620
27/08/26	CA$0.5100	-5.56%	19,000

Delayed Quote Canadian Securities Exchange

More quotes

Delayed Canadian Securities Exchange 20:54:36 02/09/2026 +03			5-day change	1st Jan Change
0.5200 ^CAD	0.00%		-3.70%	-27.78%

08-17	Defence Therapeutics Inc. Announces Executive Changes	CI
08-04	Defence Therapeutics Inc. Announces Management Changes	CI

Market Cap	33.35M 24.09M 20.79M 19.58M 17.84M 2.28B 33.6M 232M 89.97M 1.16B 90.48M 88.5M 3.82B	P/E 2024	-2.5x	P/E 2025	-9.9x
Enterprise Value	33.62M 24.29M 20.96M 19.74M 17.99M 2.29B 33.87M 234M 90.7M 1.17B 91.21M 89.22M 3.85B	EV / Sales 2024	-	EV / Sales 2025	-
Free-Float	66.13%	Yield 2024 *	-	Yield 2025	-

08-17	Defence Therapeutics Inc. Announces Executive Changes	CI
08-04	Defence Therapeutics Inc. Announces Management Changes	CI
08-04	Defence Therapeutics Inc Announces CEO Changes	CI
07-08	Defence Therapeutics Opens New Office In Hamilton To Expand Its Accum Radiopharmaceutical Platform	CI
06-03	Defence Therapeutics Inc. Announces Appointment of John Beaver to Its Board of Director	CI
06-01	Defence Therapeutics Inc. Appoints Dr. John Lambert as Board Director, Effective 1 June 2026	CI
05-30	Defence Therapeutics Inc. Announces Resignation of Dr. Sarkis Meterissian from Board, Joins Scientific Advisory Board	CI
05-22	Defence Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2026	CI
05-19	Defence Therapeutics Inc Expands In-House Adc Development Platform with Enhanced Analytical and Cellular Testing Capabilities	CI
03-06	Defence Therapeutics Inc. announced that it has received CAD 9.595 million in funding	CI
02-27	Defence Therapeutics Inc. announced that it expects to receive CAD 11 million in funding	CI
02-21	Defence Therapeutics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2025	CI
01-28	Defence Therapeutics Expands Collaboration With Canadian Nuclear Laboratories	MT

08-31	Defence Therapeutics Expands Radiopharmaceutical Development Strategy with Alpha and Beta-Emitter Programs	NE
08-17	Defence Therapeutics Strengthens Radiopharmaceutical Leadership with Appointment of Dr. Ryan Simms as Chief Operating Officer and Head of Radiopharmaceutical Programs	NE
08-04	Defence Therapeutics Appoints Dr. Amie Phinney as President and Chief Executive Officer	NE
07-08	Defence Therapeutics Opens New Office in Hamilton to Expand Its Accum Radiopharmaceutical Platform	NE
07-06	Defence Therapeutics : Opens New Office In Hamilton To Expand Its Accum Radiopharmaceutical Platform	PU

Defence Therapeutics Inc. Stock

Stocks

DTC

CA24463V1013

Biotechnology & Medical Research

Valuation : Defence Therapeutics Inc.

Chart: Defence Therapeutics Inc.

Latest news : Defence Therapeutics Inc.

Press Releases : Defence Therapeutics Inc.

News in other languages : Defence Therapeutics Inc.

Quotes and Performance

Price Extremes

Managers and Directors : Defence Therapeutics Inc.

Latest insider transactions

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

19/08/24	DEFENCE UNTERSUCHT DIE ANWENDUNG DER ACCUM®- HYDROGELTECHNOLOGIE ZUM TRANSPORT VON GLP-1 ZWECKS VERBESSERUNG DER WIRKSAMKEIT DER BEHANDLUNG VON DIABETES UND ZUM ERZIELEN EINES GEWICHTSVERLUSTS
13/08/24	KOOPERATIONSVEREINBARUNG VON DEFENCE THERAPEUTICS MIT ORANO ZUR ENTWICKLUNG DER NÄCHSTEN GENERATION DER GEZIELTEN RADIOIMMUNTHERAPIE FÜR FORTSCHRITTE BEI DER KREBSBEKÄMPFUNG
24/07/24	DEFENCE THERAPEUTICS ERHÄLT UNTERSTÜTZUNG DURCH DAS CNRI-H-PROJEKT VON CANADIAN NUCLEAR LABORATORIES ZUR BESCHLEUNIGUNG DER ENTWICKLUNG SEINES RADIOIMMUNOKONJUGAT-PROGRAMMS
08/07/24	DEFENCE ERHÄLT ‚NO OBJECTION LETTER’ VON DER KANADISCHEN GESUNDHEITSBEHÖRDE HEALTH CANADA FÜR SEINE PHASE I-STUDIE MIT ACCUM-002 (ACCUTOX) ALS MOLEKÜL ZUR KREBSBEKÄMPFUNG BEI PATIENTEN MIT MELANOMEN
01/07/24	ACCUTOX VON DEFENCE VERSTÄRKT DIE WIRKUNG VON IMMUNCHECKPOINTINHIBITOREN UND SCHAFFT SO SYNERGIEEFFEKTE

1 week	-3.70%
Current month	-3.70%
1 month	+22.35%
3 months	-13.33%
6 months	-14.75%
Current year	-27.78%

1 week	0.48	0.56
1 month	0.37	0.59
Current year	0.36	0.74
1 year	0.36	0.93
3 years	0.36	3.04
5 years	0.36	8.15
10 years	0.36	8.15

Manager	Title	Age	Since
Amie Phinney CEO	Chief Executive Officer	-	01/08/2026
Arnab De DFI	Director of Finance/CFO	55	20/12/2024
Ryan Simms COO	Chief Operating Officer	-	17/08/2026

Director	Title	Age	Since
Sébastien Plouffe CHM	Chairman	53	01/08/2026
Sarkis Meterissian BRD	Director/Board Member	64	05/01/2021
Philippe Lefrancois BRD	Director/Board Member	-	27/09/2024

Date	Insider	Type	Main position	Quantity	% Market Cap.
8/1/26 A	Amie Phinney	Option	Chief Executive Officer	200,000	0.2639%
8/1/26 A	Sébastien Plouffe	Option	Founder	200,000	0.2639%
6/3/26 A	John Beaver	Other	Director	0	0%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
DEFENCE THERAPEUTICS INC.	0.00%	-3.70%	-34.18%	-82.67%	28.35M
LONZA GROUP AG	+0.97%	-0.75%	+3.51%	+17.79%	49.74B
REVOLUTION MEDICINES, INC.	-0.40%	-3.13%	+427.93%	+519.44%	44.98B
IQVIA HOLDINGS INC.	+2.82%	+1.73%	+44.79%	+20.44%	42.52B
BEONE MEDICINES AG	+0.88%	-3.67%	+9.02%	+76.72%	40.78B
CELLTRION, INC.	-0.90%	-1.74%	+15.20%	+48.44%	32.89B
ASCENDIS PHARMA A/S	+2.15%	+6.13%	-	-	17.09B
MEDPACE HOLDINGS, INC.	+1.34%	-4.40%	+25.03%	+123.24%	16.28B
EUROFINS SCIENTIFIC SE	+1.70%	-0.05%	+18.53%	+28.09%	14.4B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	+2.81%	-1.64%	+80.01%	+42.08%	13.48B
Average	+1.14%	-1.99%	+65.54%	+88.18%	27.22B
Weighted average by Cap.	+1.03%	-2.25%	+93.88%	+128.65%

	2024	2025
Net sales	-	-
Net income	-13.19M -9.53M -8.22M -7.75M -7.06M -900M -13.29M -91.72M -35.59M -460M -35.8M -35.01M -1.51B	-3.52M -2.54M -2.2M -2.07M -1.88M -240M -3.55M -24.48M -9.5M -123M -9.56M -9.35M -404M
Net Debt	1.69M 1.22M 1.05M 992K 904K 115M 1.7M 11.75M 4.56M 58.97M 4.59M 4.48M 194M	272K 196K 169K 160K 145K 18.55M 274K 1.89M 733K 9.49M 738K 721K 31.16M